Q1 2022 Zoetis Inc Earnings Call
You limit yourself to one question and then queue up again with any follow ups.
Your line will be muted when you complete your question.
When posting your question or what's been posing your question. Please pickup your handset to allow optimal sound quality.
Lastly, if you should require operator assistance, please press star zero.
It is now my pleasure to turn the floor over to Steve Frank Steve You may begin.
Thank you operator good morning.
Everyone and welcome to the <unk> first quarter 2022 earnings call I am joined today by Kristin Peck, our Chief Executive Officer, and Whitney Joseph Our Chief Financial Officer before we begin I'll remind you that the slides presented on this call are available on the Investor Relations section of our website and that our remarks today will include forward looking.
Statements.
And that actual results could differ materially from those projections.
For a list and description of certain factors that could cause results to differ I refer you to the forward looking statements in today's press release, and our SEC filings, including but not limited to our annual report on Form 10-K.
And our reports on Form 10-Q.
Our remarks today will also include references to certain financial measures, which were not prepared in accordance with generally accepted accounting principles or U S. GAAP. A reconciliation of these non-GAAP financial measure measures to the most directly comparable U S. GAAP measures is included in the financial tables that accompany our earnings press release and the Companys 8-K.
Filing data today Thursday may five 2022, we also cite operational results, which exclude the impact of foreign exchange with that I will turn the call over to Kristin.
Thank you, Steve and welcome everyone to our first quarter earnings call for 2020 channel.
<unk> delivered a strong quarter to start the year with 9% operational revenue growth and 8% operational growth in adjusted net income driven by the strength of our companion animal portfolio, we generated similar growth for both the U S and international segments, with 9% and 8% operational growth respectively.
Our strength across parasiticide dermatology product monoclonal antibodies and diagnostics are all capitalizing on the marriage of positive trends in pet care with customer driven science coming from <unk> in the first quarter, we grew 20% operationally and our companion animal portfolio.
As we expected our livestock portfolio continued to face challenges declining 6% operationally in the quarter largely due to declines in swine product sales in China and generic competition from Jackson.
As we look at the rest of the year, we are updating our guidance to reflect the negative impact of recent changes in foreign exchange rates, but this had no impact on our previous operational growth rates and assumptions for the year.
Even as we face uncertainties related to the war in Ukraine, COVID-19, Lockdowns inflation and ongoing supply chain constraints, we remain confident in the underlying strength and performance of our business.
Our diverse portfolio global scale talented colleagues and continuous innovations remain the foundation of our long term success and durability and we continue to invest in the resources marketing programs and manufacturing capacity, we need to support our growth.
In R&D, we are building new capabilities and pipelines across our companion animal and livestock portfolios to ensure our long term performance.
In the first quarter, we continued to receive approvals for new products and indications develop lifecycle innovations for major brands and expand our portfolio into new markets.
On the livestock side of the business, we expanded our cattle vaccine portfolio with an approval in the U S. Our protiviti. The first modified live vaccine to offer protection against Mycoplasma bogus. This vaccine provides cattle producers and veterinarians with broader overall protection against bovine respiratory.
Disease.
We also gained approval in Brazil for Jackson, K P, which is it also a treatment for BRD and combines the antimicrobial properties of Jackson with the non steroidal anti inflammatory ketoprofen to rapidly reduce fever, and a single dose.
<unk> K P is also approved in the U S, Canada, and European Union, Australia, and Mexico, and it has been an important part of how we continue to distinguish the drax and brand in the face of generic competition.
In poultry, we received approval in Brazil for a pullback for third at HPT IBD, a recombinant vector vaccine that is also approved in the U S and Canada on.
On the companion animal side of the business. We received another approval for Celesio. The industry's first monoclonal antibody for osteoarthritis pain in cats, adding Australia to the U S European Union U K, Canada and Switzerland.
And another map therapy cider point received a claim extension in Canada. So it now covers both the treatment of atopic dermatitis and allergic dermatitis in dogs.
<unk> appointed Africa continued to grow significantly and expand the dermatology market as disease awareness and treatment options become more known to pet owners.
We have a strong leadership position based on our innovative science and do not believe competing products will come to market in 2022.
We also continue building our multipurpose diagnostics platform that scan images with the recent addition of blood smear testing.
Introduced in September 2020 that scan images is a first of its kind technology with a multitude of applications, including AI fecal analysis digital cytology image transfer and now AI blood smear, all helping veterinarians broadened their in clinic diagnostic offerings to provide the best.
Care possible for dogs and cats.
But the last two years I've been speaking to you about our catalysts for growth and those continue to drive our performance.
Our outlook for growth in international markets remains very positive based on our diverse global footprint and continued expansion opportunities for key brands like some pairing of trio Apple cider point Labella and Celesio.
In terms of Ukraine, we are condemned the Russian invasion from the outset, and we are deeply saddened by the senseless violence being brought upon the people of Ukraine or company colleagues and has the widest foundation have worked together to provide veterinary care medicines financial support and evacuation assistance to those in need.
With every decision even the most difficult and complex ones, we're guided by our purpose to nurture the world and humankind by advancing care for animals.
While we have suspended all investments and promotional activities in Russia. The continued care of pets and livestock remains in a central responsibility for <unk> and our colleagues and to remain focused on maintaining our critical supply of animal medicines and vaccines for veterinarians and producers there we.
We anticipate a negative impact of about 1% to our original full year growth expectations due to Ukraine, and Russia, but we are maintaining our previous operational growth rates based on the overall strength of our companion animal business and the positive momentum of expanding our U S pet care and diagnostic commercial teams.
Speaking of diagnostics another catalyst for growth, we delivered 12% operational growth in the first quarter.
We continue to invest significantly in this space to accelerate our growth for example, we've been shifting our go to market model. This year and building a dedicated field force for our diagnostics portfolio. This hiring is a significant part of a 40% increase to our total U S companion animal field force we see.
Sales force expansion as a key lever to supporting growth opportunities and our diagnostics and pet care businesses.
We also continue to see very strong growth in pet care as we expand our major companion animal brands and markets around the world.
<unk> trio is doing very well as it continues to gain market share based on veterinarians preference for an innovative triple combination parasiticide for dogs.
Pet owners have also been demonstrating strong loyalty rates after trying trio and we are excited by the ability of our direct to consumer campaigns and additional field force colleagues to increase interest in this product.
<unk> is also doing incredibly well across Europe , and we remain confident in the blockbuster potential for labella in 2022 and Celesio in the longer term as.
And we see improvements in supply, we will be launching <unk> in additional markets, such as Canada and Australia. This year.
In terms of the U S. We are still planning a launch of <unk> in the second half of year, and we anticipate approval for lowbrow up by the end of the year, assuming FDA inspections are completed at facilities outside of the U S.
Overall, we continue to benefit from pet care trends in terms of increased demand clinic revenues pet ownership and spending habits.
Finally, a brief update on supply as I mentioned last quarter, we are managing certain isolated supply constraints for la <unk>.
<unk> and some of our other products as we compete for some limited manufacturing inputs critical to human health during the pandemic we.
We're also seeing additional global supply challenges related to Russia's invasion of Ukraine, and the recent COVID-19 resurgence in China, while some of these challenges are.
Global manufacturing and supply network to mitigate any impacts to our overall business and our commercial teams are ensuring control launches for new products and coordinating with customers to minimize any impacts on their animal care.
In conclusion, we are off to a good start for the year and we're maintaining our operational growth expectations for the full year, our diverse and durable portfolio global scale and pipeline of innovations have us well positioned to meet customer needs and shareholder expectations for this year and beyond thank you.
Now, let me hand things off to Whitney.
Thank you Kristen and good morning, everyone.
We mentioned, we had a very strong start to the year with continued growth across a number of our core product franchises.
Today, I will focus my comments on our first quarter financial performance.
The key drivers contributing to our performance and provide an update on our full year 2023 guidance.
In the first quarter of regenerative revenue of $2 billion growing 6% on a reported basis and 9% on an operational basis.
Adjusted net income of $625 million grew 4% on a reported basis and 3% on an operational basis.
Of the 9% operational revenue growth, 3% from price and 6% from volume.
Volume growth of 6% consisted of 5% from new products, which includes the Barrick of trio Penn Labella.
3% from key dermatology products, while other in line products declined 2%.
The decline in other in line products was expected and largely the result of a difficult comparison to the prior year and the impact of our swine business in China.
Companion animal products led the way in terms of species growth growing 20% operationally with livestock declining 6% on an operational basis in the quarter.
Our small animal parasiticide portfolio was the largest contributor to growth in the quarter, where our innovative and diverse flea tick and heartworm portfolio drove growth of 25% operationally.
Some broker trio posted global revenue of $164 million.
Representing operational growth of 83% versus the comparable 2021 period.
In Q1, <unk> was the number one canine parasiticide sold in the U S. In terms of revenue and we recently launched <unk> in Japan, a sizeable international heartworm market.
Meanwhile, our key dermatology products <unk> and photo point have significant global growth again with $307 million of revenue, representing 28% operational growth against the robust prior year in which <unk> grew 24% in the first quarter.
In Europe , our recently launched monoclonal antibody <unk>, which is for osteoarthritis pain in dogs also meaningfully contributed to growth in the quarter posting $21 million in sales.
Our global diagnostics portfolio recorded $98 million in revenue and have operational sales growth of 12% in Q1 growing across both our U S and international segments.
Growth was largely driven globally by consumable usage and new products.
We also continue to see growth in the placement of new devices and international markets.
Diagnostics remains a key growth driver for <unk>, and we continue to make significant investments in our field force new technologies and reference lab expansion.
Our lifeboat business declined 6% operationally in the quarter a revenue decline in China swine products was a result of both declining pork prices due to increased supply and a difficult prior year comparable.
In the U S generic competition for Jackson and on favorable market conditions for producers, primarily resulting from elevated input costs also led to a decline in capital products.
Our fish portfolio again grew double digits in the quarter and along with the strength of our other emerging markets, partially offset the broader decline.
Overall lifecycle performance in the quarter was in line with our expectations.
Now moving on to revenue growth by segment for the quarter.
U S revenue again topped $1 billion in the quarter growing 9% with companion animal products growing 32% and livestock sales declining by 11%.
U S pet care fed practice trends continues to be positive with practice revenue growing approximately 5% even in the face of challenging prior year comparisons and the Amazon variant wave that impacted both visits and the availability of labor clinics in January and February .
Spending per visit increased 8% in the quarter, while visits declined 3%.
Underlying demand for veterinary care remains robust throughout the country, even as people return to work and we believe that clinic revenue will continues to grow at levels above where we were seeing prior to COVID-19 as the standard of veterinary care continues to increase through innovation better demographics higher compliance and more pets.
Companion animal growth in the U S was driven largely by sales from our parasiticide portfolio as well as key dermatology products.
Growth of <unk> was again strong in the quarter with sales of $147 million in the U S growing 77%.
We continue to meet our cleaning penetration targets and take share within individual clinics with additional runway for future revenue growth.
I don't Wanna satisfaction material is approximately 90%.
Okay.
Key dermatology product sales were $194 million for the quarter growing 23% with abaco inside a point each significantly contributing to growth.
Our investments to support the photo the portfolio have been instrumental in driving more patients into the clinic and we will continue to invest meaningfully in this space as a large portion of those with dermatitis remains undertreated, representing an opportunity to further expand the market.
In an effort to support all of our long term sustainable sources of growth in our companion animal portfolio in April we launched our new pet care go to market strategy, expanding our U S companion animal field force by approximately 40% and creating dedicated and separate diagnostics and pharma coverage for our portfolio of <unk>.
Thanks.
U S livestock declined 11% in the quarter, primarily resulting from our capital business.
This was expected as we experienced challenges from generic competition for Jackson, which didn't exist in the same quarter last year as well as elevated input costs continuing to weigh on producer profitability.
Meanwhile, our poultry business continues to be negatively impacted by the expanded use of lower cost alternatives, resulting from reduced does this pressure from smaller fox sizes as well as generic competition for <unk>.
Swine product sales grew in the quarter as a result of favorable market conditions for producers and higher this is prevalent.
Moving on to our international segment, where revenue grew 3% on a reported basis and 8% operationally in the quarter.
Companion animal revenue grew 23% operationally and last night revenue declined 3% operational.
Increased sales of companion animal products resulted from growth of our key dermatology products monoclonal antibodies will alleviation of pain and.
And our parasiticide portfolio.
Several key brands continue to benefit from our international direct to consumer campaigns in Latin America, and parts of Europe , and we remain excited with the long term prospects of these programs.
We are encouraged by the performance of our monoclonal antibody for pain, with labella generating $21 million and Valencia, delivering $3 million in first quarter sales.
The boiler remains on track to exceed $100 million in revenue this year.
As we mentioned last quarter Labella became the number one pain product in the EU in the first year of launch with the underlying performance metrics being very favorable for future growth.
Gordon rates remained at around 90% compliance exceeded our initial expectations and we continue.
Significant opportunity to extend the pain market with a meaningful percentage of dogs on liberal or being new to the market.
Meanwhile, International livestock declined 3% operationally in the quarter. This.
This decline was driven predominantly by our swine portfolio in China.
As we indicated over the past several months increased parts supply in the market. Thanks to a significant decline in pork prices, which impacts producer profitability.
In addition, our first quarter of 2021 presented a difficult comparative period as pricing and producer profitability in that quarter have been at an all time high.
While we expect China to return to growth in the back half of the year, we anticipate a challenging second quarter for our swine portfolio.
Partially offsetting our decline in swine was growth in our fish poultry and cattle portfolios.
Our fish portfolio grew double digits again, this quarter driven by growth of the Alpha flux sea lice treatment products and offer <unk> <unk> vaccine for Srs in Chile.
Sales of cattle products grew in key markets due to favorable market conditions and pricing in Brazil, and Australia as well as demand generation efforts in emerging markets, such as Turkey and China.
Now moving onto the rest of the P&L for the quarter.
Adjusted gross margin of 71, 6% improved 60 basis points on a reported basis compared to the prior year, resulting from favorable product mix price foreign exchange and lower inventory charges. This was partially offset by higher manufacturing and freight.
Adjusted operating expenses increased 14% operationally with SG&A growth of 16% operationally driven by head count related compensation costs.
Advertising and promotion as well as direct to pet owner campaigns for key brands.
R&D expenses increased 4% operationally due to higher compensation costs.
The adjusted effective tax rate for the quarter was 18, 9% a decrease of 20 basis points driven by the impact of favorable discrete tax items and settlements with certain Texas authorities slightly offset by changes in the jurisdictional mix of earnings.
And finally, adjusted net income grew 8% operationally and adjusted diluted EPS grew 9% operationally for the quarter.
Capital expenditures in the first quarter were $115 million, we are still anticipating a significant increase in capital expenditures for the full year 2022, primarily related to investments in Ireland, the U S and China to support manufacturing capacity needed to meet our long term growth demands.
In the quarter, we returned over half a billion dollars to shareholders through a combination of share repurchases and dividends.
We purchased approximately 361 million shares.
Representing our largest dollar based quarterly share repurchase ever.
Now moving on to guidance for the full year 2022.
Foreign exchange rates on our updated guidance are as of late April and reflect the recent strengthening of the U S. Dollar.
Please note that any update to our full year guidance are related directly and owning to foreign exchange and that the ranges of our operational growth rates for revenue of 9% to 11% and adjusted income of 10% to 13% remain the same as our previous February guidance.
We are holding these top and bottomline operational growth rates. The same despite the conflict in Russia, and Ukraine negatively impacting our expected full year operational growth by 1%. We feel we can offset this impact with the strength of our companion animal portfolio.
Beginning with revenue for the full year of 2022, we are decreasing both the low and high end of the range by $100 million to reflect the impact of foreign exchange.
We are now projecting revenue of between 8225 and $8 $3 75 billion, while maintaining our expected operational growth of 9% to 11%.
Our adjusted net income for the full year 2022, we are decreasing.
Adjusted net income is now expected to be in the range of $2 30 652.420 billion.
While maintaining our expected operational growth of 10% to 13%.
And finally, we expect adjusted diluted EPS to be in the range of $4 99 to.
To $5.09 and reported diluted EPS to be in the range of $4 65.
To $4 77.
Sales of companion animal products will be the primary growth driver in 2022 with the continued strength of our diverse parasiticide portfolio further expansion of our key dermatology products the adoption of our monoclonal antibodies for pain and growth in point of care diagnostics.
We also continue to see a very favorable global companion animal backdrop for 2022.
For livestock, the fundamental macro trends, which make animal protein on a central business remain intact, and we believe more normalized growth will occur in 2023.
While our guidance represents our expectations for the full year I would like to provide some color on the expected phasing of growth for the remainder of 2022.
We expect top line operational growth for Q2 to be slightly below Q1 as regional restrictions related to COVID-19 in China temporarily pressured day to day business and certain supply chain activities.
We also expect a similar foreign exchange impact in Q2 that we experienced in Q1, where our reported revenue was negatively impacted by about 3%.
In addition, the significant investments we are making early in the year to support future revenue growth, including field force expansion in the U S and incremental DTC advertising will drive opex growth in Q2 at a faster rate than revenue impact in Q2, bottomline profitability more materially than in the back half of the year.
We expect that foreign exchange in Q2, we will have a negative impact to the bottom line of about 5%.
Our full year 2022 guidance once again reflects our value proposition of growing revenue in line with or faster than the market and growing adjusted net income faster than revenue.
Our success is derived from our diversified portfolio of enduring brands driven by multiple sources of inline growth and agile and disciplined innovation engine and our infrastructure to develop and expand markets globally. We expect to continue to execute across multiple dimensions of our business and capitalize on favorable end market dynamics for the <unk>.
Seeable future.
Now I'll hand things over to the operator to open the line for your questions operator.
If you would like to ask a question at this time. Please press star one on your Touchtone phone.
At any point. Your question has been answered you may remove yourself from the queue by pressing the pound key.
In the interest of time, we ask that you limit yourself to one question and then queue up again with any follow ups. Your line will be muted when you complete your question.
When posing your question. Please pickup your handset to allow for optimal sound quality.
Our first question is coming from Erin Wright of Morgan Stanley .
Okay. Thanks.
My questions I have one on companion animal trends today that I have to ask you. What are you seeing at the clinic level. If you could parse out a little bit more on what you're seeing across the U S and international in terms of demand trends, what youre seeing in terms of capacity constraints at the vet clinic level.
What is implied in your guidance at this point in terms of operational growth across across the companion animal segment, and then a follow up on trio.
Hey, I guess, where do you stand now in terms of market share market share in canine parasiticide at this point.
And how much do you think kitchen package here, taking share versus versus expanding the market with greater compliance. Thanks.
Hey, Aaron it's great to hear from you. So I mean, we fundamentally and structurally believes the pet care industry is in great shape I think as you've seen some of these trends over the last few years, there's a very high standard of care. The demographics of who is adopting these patch over the last few years.
Millennials the number of pets, you have out there and honestly the ageing of pets. So we do not think there is a demand problem.
I think you saw in the quarter or potentially a difficult comp to what you saw last year and if you look overall, a 5% increase.
That clinic, there is a little bit less traffic as you referenced I think those are some of the shorter term capacity constraints, but remember we've got a lot more pets. So youre really the base is much larger than it's historically been but given omnicom. There was definitely some challenges at some of the vet clinics.
But the other thing to consider about the data that we would just highlight is that it really pulls out a lot of the large corporates, who have found more innovative ways.
Two structured our business to add more capacity and I think youll see more of that coming overall, there where the short term labor shortages.
The other thing to really focus on we would say is if you look at the <unk> business, it's a little different the nature of our business and our innovation, we have a lot of chronic medications. It doesn't require tons visits. So we spoke a little bit more on the spend per visit as we look at it. We also have alternative channels, which for us in the quarter grew 34% so.
We remain very optimistic with regards to pet care trends overall, and maybe what you can take a second question on <unk>, Yes, sure Erin look very very pleased with the performance of <unk> trio.
Posting a $164 million of revenue in the quarter up 83% became the number one canine parasiticide in the U S and as we've shared before we are 90% penetration across <unk>.
Large corporate accounts et cetera, and within those penetrated clinics, we continued to take share as well satisfaction level with our product is about 90% among pet owners and we also just launched.
<unk> in Japan, which is a key heartworm market as well.
In the middle of this quarter so.
We're pleased with the performance material.
Our next question comes from Kristine <unk> William Blair.
Hi, Thanks for the question Iris chip.
Maybe if I could have an update on diagnostics contribution to the quarter and overall performance is good tracking with your expectations and can you comment on system placements versus testing volume growth and if you've made any additional reference lab purchases. Thank you.
Yes, sure I'll take this a christine thanks for the question look.
Pleased with the performance of our diagnostics business in the quarter, we grew our 12% posting $98 million of revenue really saw strong growth across both U S and international.
Replacements as well as consumables. So we're very pleased with the performance of the business.
Terms of.
Our reference lab acquisitions, we did not have any.
In the quarter, obviously, we've made a number of acquisitions that we that we are.
In the U S.
And continue to make investments across technology, you might've seen images. For example, we've added additional indications here with blood smear. In addition to FICO and digits digital cytology. So we'll continue to be very pleased with the performance of the business.
Our next question comes from Louise Chen Cantor.
Hi, congratulations on the quarter and thanks for taking my question just curious what has been the impact of inflation on your animal health business, both companion and livestock and how do you see potential increase in inflation or continued inflation impacting your business going forward. Thank you.
Thanks, Louise I'll start and then.
Moving to Whitney.
We have seen historically that pet owner spending has been incredibly durable.
Right now we've got about 63% of our revenue in companion animal and you can see a little more impact from inflation on the livestock side.
But if you look at the hybrid research, 86% of pet owners would spend whatever it takes so we do see inflation and when you can certainly get into how we've taken price et cetera.
But I think we obviously, it's an increase in labor cost and freight and fuel, but when he can really talk about the fact that we've been able to leverage price, especially in our companion animal business I Wonder if you want to go over some of those numbers, yes sure given we continue to see very strong underlying demand from pet owners, we are very innovative.
<unk> across our portfolio, we've been able to demonstrate that we can take price at or above inflation levels in the past and we don't see any reason why we wouldn't do that now if you look at this quarter. For example, our total growth included 3% of price by a few parse that out and you look at just companion animal globally, we took 6% of price and so we will.
Turning to use that lever.
As we proceed but given the dynamics Christian just mentioned underlying stress in the market. We will continue to have that available to us and the only thing I'd add there is despite inflation I would just note that in 2021, we increased our margins and our guidance for 2022 does the same so I think it really shows the durability the resilience of our industry.
Great.
Okay.
Our next question comes from Nathan Rich with Goldman Sachs.
Hi, good morning, Thanks for the questions.
Kristen I'd be curious to get your view.
Following up on the commentary you have on just.
Visit trends and vet spending trends.
Or do you see more variability in sales for your products that are administered need to be administered by the vet and can you just remind us how big of a percentage of your companion animal business.
That is and then a quick follow up for what knee.
It looks like the revenue guidance came down by 100 million it looks like operating profits maybe down by $50 million does.
It seems like a high decremental margin on the revenue reduction I guess does that just reflect kind of the composition of the expense space just to be curious kind of any color you can shed on that dynamic. Thank you.
Sure.
Fair enough for your first question again.
If you look at the our overall portfolio and the nature of our business I think the level of innovation, we're not as susceptible to that.
Brent you guys highlight what percentage it has to be administered in the vet clinic I don't know maybe around 50% that would be vaccines injectables, but I think if you look at the sales of <unk> being now the number one pain product.
In Europe , clearly for things that are really important to pet owners. They are getting into the clinic regular check for vaccines were not seeing any significantly negative trends. There. So I think chronic medications, which is a huge part of our business and if you look at dermatology and parasiticide, which are growing at Paris are growing at 25% in the <unk>.
Order derm at 28% in the quarter were clearly not really suffering from the.
The slight decline in the U S and that does that that trends, but maybe when you can take that second question, yes sure.
As we've said we've revised our guidance solely to reflect FX, we continue to maintain our operational guidance range, both top and bottom.
For the company that we came into in February that we gave so from an FX perspective topline impact was about 3% that's about $260 million of an impact and as you as you referenced the change you're reflecting the change in FX has a wider impact on the bottom and that's really largely driven by FX gains and losses.
Given our exposure across certain currencies, particularly the euro if you look at the first quarter. For example, you see a wider impact to the bottom than you see at the top driven by by the by the impact of.
Of that as well.
Yeah.
Our next question comes from Michael Riskin of Bank of America.
Hey, guys. Thanks for taking my question and congrats on the strong results I wanted to start with livestock markets I mean, we've known.
<unk> stock was what's going to be weak for a while.
And so theres not a huge surprise, but still just wanted to get an update on how you're seeing.
A couple of factors theyre going to do.
Jackson.
Are you still sort of projecting lapping tough comps around the summer and sort of what are your expectations for <unk> exiting this year and next year and then broader condition. So chose.
Out in the Midwest in the United States rising input costs, how do you see that playing out for U S livestock and internationally.
And then a follow up question for Rodney if I might.
You guys touched a number of times in the prepared remarks on field force expansions around investing in growth investing in the opportunities in companion animal.
Just wondering if you could go into little more detail on.
How that's going to play out when do you see that.
Showing up in the numbers when do you think you'll start seeing the payoff for that and just sort of talk about labor pressures wage pressures how that affects your thought process. There. Thanks, Greg Mike I'll take that first part of it which is the broader livestock trends and then what you can take the draftsmen.
First question on that you've got meaningful as you know well historically livestock is growing around 4% I think as you look at 2019 and 2020, you saw sort of some unusual events that affected overall industry livestock growth, obviously African swine fever in China as you remember and then overall COVID-19, but then as I think as you look.
At 2021 and 2022.
The awareness has been unusually impacted and that has everything to do with where Jackson is.
What he can get into the numbers, but that has played out exactly how we expected it to our long term outlook as well you mentioned a few minutes ago. In his prepared remarks remains unchanged, we think youre going to start to go back to more normalized growth in 2023 and beyond basically because feeding the world is a powerful trend the desire for protein and higher quality protein but.
Let me, let me get into some of the specifics on the drop the numbers and then your second question, yes. So as we said from the very beginning with recycled Jackson, we expect it to have about a 20% impact to the top line in the first year and another 20% in the second so what we're seeing across livestock right. Now is playing out exactly as we thought in fact in 2021 with a little bit slightly.
Other than that with respect to Jackson.
And we continue to have the effects positive effects of lifecycle innovation like Jackson J P and we're maintaining most of our volume and the margins for Jackson remains very attractive for us as well. So so as we expected we've seen competitors come in.
The performance has been at or slightly better than we than we expected broadly speaking I think if you look at <unk> for example, in China that was a pretty significant effect impact on the quarter with respect to livestock again, we expected that coming in and its really looking at where swine prices are in China versus a year ago, where they were at all time highs and had been at all time lows essentially.
Here in the Lockdowns are having an impact on on sort of the demand and consumption as well.
In this case so.
With respect to the field force if I can transition to that part of your question.
We're pleased to be able to expand.
To expand our field force here, we have the broadest portfolio.
Across the market.
And if you look at <unk>.
Innovation that we have coming as well with respect to the pain franchises for Celesio is that we are launching across the second half of this year and as we get approval for the gorilla in loss data as well in the U S. We continue to have opportunities to really capitalize on the market dynamics and the strong demand that we see and have and have additional field force, which.
We see a strong return on those as well we are also launching a dedicated field force for diagnostics separate and apart from our for our Rx teams, which we believe we'll have again a very positive return.
For us as well now you can see that with those plans, we still have an operational and Levered P&L, where we're growing the bottom line.
The top line so a topline of nine to 11 in the bottom of 10 to 13 with approximately a 40% increase in our field force.
Our next question comes from Jon Block of Stifel.
Great Hey, guys. Good morning, maybe just a couple quick ones for U S Library approval was that a slight push Christian to year end 'twenty two for mid 'twenty. Two if it was maybe just if you could elaborate on what's still needs to get done there for approval in <unk> and 'twenty two.
How are you from a supply standpoint, do you think that product will be ready for early 2023 U S launch and then maybe just as a quick follow up can you talk about the supply chain and cost and how you feel there.
The animals expect it to be a big year over year and 22. So you've got this positive mix shift you've got price running ahead of what it normally does and then you called out 3% versus 1% last year and GM is still expected to be flattish. So just would love some color on how youre filling in the supply chain.
Sure. Thanks, John I'll start with the first question and then let me take the second.
We congratulate broiler know Abbott.
It's exactly as we expected.
Were expecting an approval later this year, we continue to expect that as we wrote in the box. There is no change there we still require an ex U S site visit as we said all along so I would say there is really no update there.
To your second question when would you expect to launch our obviously as we would in any product working to buildup supply, but as always in our industry and especially with regards to biologics monoclonal antibodies. The standard in our industry is it takes somewhere between three and nine months to get up to a full lifestyle I think what you should expect next year as well obviously similar to what we've done for every other product.
It's a monoclonal antibody will do an early experience sometime in the first half again, depending on where it was a privilege and a launch shortly thereafter, we're quite excited about it obviously, we're working hard to build up that supply as soon as we get the approvals of the site et cetera.
Everything I Love Rolla is exactly where we were before.
Absolutely no change there.
Yes, and I'll take the supply chain.
The question is on look.
Our supply chain has proven to be very resilient.
Challenging elements over the last couple of years, we delivered 15% operational growth last year with 14 of that being volume. So we've proven our ability to continue to have to navigate through those currently we are we are looking at China. For example, where the Lockdowns have had an effect certainly in our first quarter and we see that.
Our second quarter as well, which is why we include those in our prepared commentary around Q2 expectations, but in terms of price. We aren't we are pulling that lever saw 3% total for the company on the companion animal side, which now is about 63% of our company. If you look at Q. If you look at the first quarter.
Companion animals growing almost 50% over the last two years, if you look back through 2019 levels. So.
Against very strong market dynamics and demand we.
We do see.
The mixture of being very positive for us with more companion animal and with our innovative products that are launching as well, but we do have some offsets when you look at livestock, particularly Jackson as we've just talked about in line with our expectations, but certainly are giving price and maintaining the volume and as I said, it's still an attractive margins for us.
That's really the main offset if you look at it.
Across the year.
Okay.
Our next question comes from <unk> Prasad Barclays.
Hi, good morning, and thanks for the questions.
One one each on.
Some ban on livestock, firstly on atopic dermatitis I estimate that you currently probably around $35 from the market share in the U S between.
Syed appointed <unk>, so with the one.
Most of the incremental marketers allergic dermatitis and those market open for you as you get the label extension on the same subject do you also have an update on your oral JAK inhibitors.
Which is expected to come later this year.
That would include your market share if at all.
On the livestock side could you quantify if there are any opportunities that are coming to you to the Chinese consumption shifting towards beef and poultry will be swine.
Or is there is not much of a trend there.
Sure I'll start on the overall derm as you saw it grew about 28% in the quarter drill.
Driven by expanding our direct to consumer efforts.
Certainly you see we're investing more in our field force a.
Pet care rewards I also think genuinely it's just more people home with our pets.
I don't have the specific share numbers, we can certainly get back to you on that.
I think it's over 70% in the U S. Our share of the atopic dermatitis allergic dermatitis market overall in the U S.
And especially as you know thats, even more if you want to look at revenue, but we're really pleased with where that's going.
With regards to competition I know our favorite question, we don't absolutely now we would expect competition on it at this point in time is as we look at 2022, we are not expecting competition in 2020, we would expect it in 2023 is our latest intelligence, obviously, we could be wrong there.
Our current expectation is competition for <unk> on a small molecule basis will come in 2023 with regards to our own pipeline internally, we don't discuss that so I don't think we have any color. There I don't know if you want to take the second question, Yes, sure just one thing to add on the first one for US really when we look at <unk>, it's less about market share. It's a lot more about market expansion.
Certainly an opportunity when we look at the number of doors that suffer from initiatives that are now being treated.
About $6 million of the seven six that are being cheated a good portion of them are under treated with either.
Antihistamine or steroids. So we do think there is an opportunity with respect to the on the treatment. There now I'll shift over to your question around livestock, particularly around China, we have seen an increase in beef consumption.
Here, which certainly benefits us when you look at our business in Brazil for example that exports into China from a lease perspective as well as in China.
There are activities and so it's still in terms of in China is still relatively small compared to <unk>. For example, but we are seeing good trends there that are favorable to us.
Yeah.
Yeah.
Our next question comes from Chris Schott of JP Morgan.
Great. Thanks, so much for the questions just two for me.
First can you just remind us about your sensitivity to economic growth I know youre seeing very healthy demand in the companion side right now and you've been able to take price, but if we enter a mild recession in some parts of the world, particularly Europe , what type of pressures would you anticipate if any to your business from that and my second one was on protein demand I know you've touched on this in a couple of them.
Questions, but it does seem like we're entering a kind of a challenging macro environment with crude prices growing very rapidly, especially in the emerging markets do you see that as a risk at all in terms of global protein demands and consumers.
Trading down on protein.
That could kind of dampen kind of your livestock recovery as we look out to kind of 2023 and beyond thanks. So much.
Sure. Thanks, Chris Good to hear from you as you think about the economic challenges.
Potential for economic risks across the Globe I think one thing <unk> seen about the animal health industry that is referencing before.
The research is 86% will spend what it takes and I think it's also really important to focus on the fact that.
Our companion animal business is 50 is growing 50% between 2019 and 2021 is when you mentioned it was about 63% and that is just a more durable business and as you think about getting through economic challenges. We grew through the beginning of Covid for example.
As you put it.
If you look at it.
Grown during the great recession, and that was one of our companion animal business was only 35%.
So I think structurally.
If you look at our business, it's more positive now than it was during the great recession. So I do think we're going to be pretty resilient.
I'll go through those times, but.
But I'll, let you know.
Let me add anything there if he wants to on that take care of our protein demand for that question, Yes, I think you've covered it well just a companion animal.
The bigger percentage of our business now is proven to be very resilient as structurally with respect to demographics, we have more gen Z and millennials owning pets more pets and if you look across our portfolio a number of chronic conditions that we're treating that are very resilient, even as we've seen in the past and structurally given strong.
Now with respect to livestock, you do see the potential for people to trade down and Fourteens gone from beef down too.
Shaken, our pork and et cetera. So we do we do think.
That can happen in terms of looking across the globe, we do have a broad portfolio across different species, obviously, but that was one of the areas that we think is.
A little bit less than what we see in companion animal words is extremely resilient no. We do overall, though when you look at protein consumption, we do see that growing over time, particularly as you could look across emerging markets.
Growing populations.
Increase in sort of disposable income et cetera, and a growing middle class across across different markets, we'd see those continuing to maintain our growth is with respect to supporting consumption. We do have the pandemic, which actually has been negative from a lifestyle perspective I think.
Let's look at the pandemic and think about the positive.
On the companion animal side, but that has actually been largely negative and so we do believe that the <unk>.
Two our Jackson, which we've talked about but we do anticipate a return to growth in livestock as we get out into 2023 24 timeframe.
Our next question comes from Steve Scala of Cowen.
Thank you you mentioned enhanced spending per pet our understanding is that this is due to two things enhanced compliance and catch up and routine wellness checks is that what you've seen if so how much does each contribute so how much does enhance compliance contribute versus <unk>.
It's up in routine visits the concern is that the catch up in routine visits would seem like a one time boost and if thats. The case then what are the long term implications of not no longer getting that boost and just enjoying the trends of the enhanced compliance.
Sure I mean, I guess, we would say is that youre seeing more animals.
That's why he has mentioned the demographics of who is adopting these animals people, who spend more time more money on them and the aging of Pat So I'm not sure we would probably parts of the data the way you do to be perfectly honest. Obviously, we are seeing increased compliance I think alternative channels.
Sort of online an auto ship even from clinics is really helping driving that increased compliance, but I would say if you look at our portfolio. It's innovation, it's bringing disruptive innovation that people are excited about looking at Perez a single product that does three things.
We're excited about you look at monoclonal antibodies you look at dermatology, we have great chronic medications that are not as susceptible to how many visits you make if you get a prescription prepared it lapped the year. So I guess, we would look at the data slightly differently than what you are looking at it and more importantly for our business, we think the nature of our business and the level.
All of innovation and the demographics of both the number of animals and who's adopting them remains very positive.
Yes, I would say, it's a combination of just an increased standard of care.
For animals, particularly for pets aided by the innovation, that's come out of <unk> across derm and.
Paris, who decides and now with pain.
And the Democratic graphics of the owners that actually put a premium on the health of their pets.
Driving this and I think people are doing more in those visits as well, which is driving sort of the revenue per visit figures that you see which is again part of the reason that we don't think that the business themselves or as meaningful as the spend per visit.
Okay.
Our next question comes from Elliot Wilbur of Raymond James.
Thanks, Good morning.
To ask.
Your line of questioning around the.
EU launch experience and dynamics to date with respect to labella and <unk> just some of the early experience is shaping expectations for the U S launch areas of over underperformance, where <unk> been positively surprised and just thinking about dynamic.
Such as persistence do you have any sense of.
The number of patients started on therapy that are that are.
We are returning for follow up injections labella share of new patient starts.
And I know, it's still relatively early but is or are you seeing or are you expecting to see an increase in overall <unk>.
Patient volumes from the launch of these products that and just as a quick follow up here, how important was or is the nab opportunity in the U S. In terms of driving your decision behind the sales force expansion.
Sure. Thanks Elliot great questions on Libra, we are super excited at the launch there.
To get to some of the specific information you asked for as we said this is now <unk> in Europe is now the number one selling product for pain, what's really exciting also about that is 40% are patients that are new to the category. So I think this is really changing the game for a lot of people maybe for safety reasons Couldnt take what the other product where are really coming into the <unk>.
Nick and to get to your other question. There is a 90% reorder rate. So when you get that when you come in for one injection are you staying with the product. The answer is yes, and this is why we believe in its first full year in Europe alone <unk> will be a blockbuster product for us we did about $22 million in Q1. This definitely does.
Inform as we think about a U S launch.
That's why we want to start with early experience getting.
Each of them Thats, especially the Kols you see what it looks like you know how to treat you know how to manage it and then really building that excitement, which worked incredibly well for us in Europe , which will do again in the U S and really I think our expectations for the product has increased based on the success. We've seen already so let's yes, we're very excited as well, it's a very different market.
It didn't exist before.
As we've talked about we're really create a mark creating market awareness has demonstrated time and again its ability to do that as it did in term, but again, you've got to get the cat to the clinic because you know there are less medicalized mandal, you've got to help <unk>.
Cat owners know what paint looks like but we remain super excited about Valencia. It will just be as we said the ramp will look slightly different answer lumpier than it does with labella, but we're just as excited and we think its potential is.
Very strong there do you want to add anything let me know just that part of the question on the field Force I wanted to just make a comment.
Comment on which is look we have the broadest portfolio as I mentioned before.
For and we continue to add innovative products to that and so we carefully analyze sort of the coverage across clinics and across products. Our field force and I'm very confident that this is an investment that's going to have that's going to yield positive returns for us.
Across our product fleet existing product opportunities to expand in the existing products as well as new products that are coming on.
This concludes our question and answer session. At this time I'd be happy to return the call to Kristin Peck CEO for any concluding remarks.
Great. Thank you all for your questions and for the continued interest in <unk> I just wanted to summarize I think the wireless is off to a strong start of the year. We've got continued strength in products for pet care and I think as you've seen a diverse and durable global portfolio.
Happy to be maintaining our operational growth expectations for the full year. Despite the negative impact of foreign exchange and other headwinds and we're continuing to make ongoing investments in talent and technology manufacturing expansion and innovation that have us well positioned to support our future growth plans as well. So I look forward to keeping you updated on future calls and hope you have a great day.
Thanks, so much everybody.
Yes.
This does conclude todays <unk> Q1, 2022 earnings call and webcast you may now disconnect and everyone have a great day.